Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomised Trial to Evaluate the Benefit of Adjuvant Hormonal Treatment With Leuprorelin Acetate (Eligard® 45 mg) for 24 Months After Radical Prostatectomy in Patients With High Risk of Recurrence.

NCT01442246 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT01442246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01442246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomised Trial to Evaluate the Benefit of Adjuvant Hormonal Treatment With Leuprorelin Acetate (Eligard® 45 mg) for 24 Months After Radical Prostatectomy in Patients With High Risk of Recurrence.
Lead sponsor
UNICANCER
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 31, 2011
Completion date
September 30, 2027
Enrollment
700 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

metastases